227 related articles for article (PubMed ID: 21193945)
1. OLIG2 is differentially expressed in pediatric astrocytic and in ependymal neoplasms.
Otero JJ; Rowitch D; Vandenberg S
J Neurooncol; 2011 Sep; 104(2):423-38. PubMed ID: 21193945
[TBL] [Abstract][Full Text] [Related]
2. The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas.
Ligon KL; Alberta JA; Kho AT; Weiss J; Kwaan MR; Nutt CL; Louis DN; Stiles CD; Rowitch DH
J Neuropathol Exp Neurol; 2004 May; 63(5):499-509. PubMed ID: 15198128
[TBL] [Abstract][Full Text] [Related]
3. SOX10 and Olig2 as negative markers for the diagnosis of ependymomas: An immunohistochemical study of 98 glial tumors.
Švajdler M; Rychlý B; Mezencev R; Fröhlichová L; Bednárová A; Pataky F; Daum O
Histol Histopathol; 2016 Jan; 31(1):95-102. PubMed ID: 26287936
[TBL] [Abstract][Full Text] [Related]
4. Olig2 and CD99 are useful negative markers for the diagnosis of brain tumors.
Ishizawa K; Komori T; Shimada S; Hirose T
Clin Neuropathol; 2008; 27(3):118-28. PubMed ID: 18552083
[TBL] [Abstract][Full Text] [Related]
5. Shared oligodendrocyte lineage gene expression in gliomas and oligodendrocyte progenitor cells.
Bouvier C; Bartoli C; Aguirre-Cruz L; Virard I; Colin C; Fernandez C; Gouvernet J; Figarella-Branger D
J Neurosurg; 2003 Aug; 99(2):344-50. PubMed ID: 12924709
[TBL] [Abstract][Full Text] [Related]
6. Utility of combining OLIG2 and SOX10 IHC expression in CNS tumours: promising biomarkers for subtyping paediatric- and adult-type gliomas.
Aboubakr O; Métais A; Maillard J; Hasty L; Brigot E; Berthaud C; Lacombe J; Pucelle N; Raynal J; Appay R; Varlet P; Tauziède-Espariat A
Histopathology; 2024 Apr; 84(5):893-899. PubMed ID: 38253970
[TBL] [Abstract][Full Text] [Related]
7. Diversity of glial cell components in pilocytic astrocytoma.
Tanaka Y; Sasaki A; Ishiuchi S; Nakazato Y
Neuropathology; 2008 Aug; 28(4):399-407. PubMed ID: 18312545
[TBL] [Abstract][Full Text] [Related]
8. Predominant expression of OLIG2 over ID2 in oligodendroglial tumors.
Mikami S; Hirose Y; Yoshida K; Kawase T; Ohnishi A; Nagashima K; Mukai M; Okada Y; Ikeda E
Virchows Arch; 2007 May; 450(5):575-84. PubMed ID: 17431671
[TBL] [Abstract][Full Text] [Related]
9. Expression of the oligodendroglial lineage-associated markers Olig1 and Olig2 in different types of human gliomas.
Ohnishi A; Sawa H; Tsuda M; Sawamura Y; Itoh T; Iwasaki Y; Nagashima K
J Neuropathol Exp Neurol; 2003 Oct; 62(10):1052-9. PubMed ID: 14575240
[TBL] [Abstract][Full Text] [Related]
10. Expression of oligodendrocyte lineage genes in oligodendroglial and astrocytic gliomas.
Riemenschneider MJ; Koy TH; Reifenberger G
Acta Neuropathol; 2004 Mar; 107(3):277-82. PubMed ID: 14730454
[TBL] [Abstract][Full Text] [Related]
11. Subtyping of gliomas of various WHO grades by the application of immunohistochemistry.
Popova SN; Bergqvist M; Dimberg A; Edqvist PH; Ekman S; Hesselager G; Ponten F; Smits A; Sooman L; Alafuzoff I
Histopathology; 2014 Feb; 64(3):365-79. PubMed ID: 24410805
[TBL] [Abstract][Full Text] [Related]
12. Clinical association analysis of ependymomas and pilocytic astrocytomas reveals elevated FGFR3 and FGFR1 expression in aggressive ependymomas.
Lehtinen B; Raita A; Kesseli J; Annala M; Nordfors K; Yli-Harja O; Zhang W; Visakorpi T; Nykter M; Haapasalo H; Granberg KJ
BMC Cancer; 2017 May; 17(1):310. PubMed ID: 28468611
[TBL] [Abstract][Full Text] [Related]
13. Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2.
Rousseau A; Nutt CL; Betensky RA; Iafrate AJ; Han M; Ligon KL; Rowitch DH; Louis DN
J Neuropathol Exp Neurol; 2006 Dec; 65(12):1149-56. PubMed ID: 17146289
[TBL] [Abstract][Full Text] [Related]
14. Expression of interleukin-1beta mRNA and protein in human gliomas assessed by RT-PCR and immunohistochemistry.
Sasaki A; Tamura M; Hasegawa M; Ishiuchi S; Hirato J; Nakazato Y
J Neuropathol Exp Neurol; 1998 Jul; 57(7):653-63. PubMed ID: 9690669
[TBL] [Abstract][Full Text] [Related]
15. Olig2 expression, GFAP, p53 and 1p loss analysis contribute to glioma subclassification.
Mokhtari K; Paris S; Aguirre-Cruz L; Privat N; Crinière E; Marie Y; Hauw JJ; Kujas M; Rowitch D; Hoang-Xuan K; Delattre JY; Sanson M
Neuropathol Appl Neurobiol; 2005 Feb; 31(1):62-9. PubMed ID: 15634232
[TBL] [Abstract][Full Text] [Related]
16. OLIG2 as a specific marker of oligodendroglial tumour cells.
Marie Y; Sanson M; Mokhtari K; Leuraud P; Kujas M; Delattre JY; Poirier J; Zalc B; Hoang-Xuan K
Lancet; 2001 Jul; 358(9278):298-300. PubMed ID: 11498220
[TBL] [Abstract][Full Text] [Related]
17. Quantitative analysis of mitotic Olig2 cells in adult human brain and gliomas: implications for glioma histogenesis and biology.
Rhee W; Ray S; Yokoo H; Hoane ME; Lee CC; Mikheev AM; Horner PJ; Rostomily RC
Glia; 2009 Apr; 57(5):510-23. PubMed ID: 18837053
[TBL] [Abstract][Full Text] [Related]
18. Anti-human Olig2 antibody as a useful immunohistochemical marker of normal oligodendrocytes and gliomas.
Yokoo H; Nobusawa S; Takebayashi H; Ikenaka K; Isoda K; Kamiya M; Sasaki A; Hirato J; Nakazato Y
Am J Pathol; 2004 May; 164(5):1717-25. PubMed ID: 15111318
[TBL] [Abstract][Full Text] [Related]
19. Low grade diffuse gliomas: shared cellular composition and morphometric differences.
Kinjo S; Hirato J; Nakazato Y
Neuropathology; 2008 Oct; 28(5):455-65. PubMed ID: 18282166
[TBL] [Abstract][Full Text] [Related]
20. The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.
Solga AC; Toonen JA; Pan Y; Cimino PJ; Ma Y; Castillon GA; Gianino SM; Ellisman MH; Lee DY; Gutmann DH
Oncotarget; 2017 Jul; 8(29):47206-47215. PubMed ID: 28525381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]